AI-Powered Neoantigen Discovery Platform
LNEA™ integrates tumor-normal sequencing, somatic mutation identification, HLA typing, MHC-binding prediction, immunogenicity assessment and target prioritization to identify patient-specific therapeutic neoantigens.
Tumor & normal tissue sequencing
Somatic mutation identification HLA typing
Candidate neoantigen generation MHC-binding prediction Immunogenicity assessment
Neoantigen ranking Personalized target selection
Personalized Neoantigen mRNA DC Vaccine
Neoantigens are identified based on each patient’s tumor.
Selected neoantigen sequences are encoded in a personalized mRNA construct.
Personalized neoantigen mRNA is delivered through autologous dendritic cells.
Designed to induce neoantigen-specific T-cell responses.
Mar 2023NMPA IND clearance.
Feb 2025U.S. FDA IND clearance.
Personalized Multi-Target Neoantigen-Specific T-Cell Therapy
Targets up to 30 neoantigens to help limit tumor escape.
Includes both CD4+ and CD8+ neoantigen-specific T cells.
Uses peripheral blood without requiring tumor tissue collection for manufacturing.
No lentiviral transduction required.
From Patient Sample to Personalized Therapy
Tumor and normal tissue sequencing
Mutation identification and neoantigen prediction
Target prioritization and personalized therapeutic design
Personalized GMP manufacturing and release
Clinical treatment, patient outcome data, and learning
